NEW YORK (GenomeWeb) – Large-scale mutational tumor profiling of advanced cancer patients treated at Memorial Sloan Kettering Cancer Center has allowed a significant number of patients to enroll in trials of targeted treatments and may help predict patients’ response to immunotherapy, according to a new study.
In the paper, published in Nature Medicine yesterday, a large team of clinicians and researchers at the center reported that about a third of the first 10,336 patients profiled with its targeted next-generation sequencing test, MSK-IMPACT, harbored actionable mutations and 11 percent of patients participated in a genomically matched clinical trial based on their results. The data, some of which were presented at a meeting last year, and which the center is sharing with the scientific and clinical community, can also help with research, particularly of rare cancer types.
“It’s a milestone for us in terms of the number of patients for who we’ve been able to offer comprehensive testing,” said Michael Berger, associate director of the Marie-Josée and Henry R. Kravis Center for Molecular Oncology at Memorial Sloan Kettering and the senior author of the study.
The study includes results from patients who received MSK-IMPACT between January 2014 and May 2016, and it